Isoxanthohumol

Isoxanthohumol

SCHEMBL29743582

COc1cc(O)c(CC=C(C)C)c2c1C(=O)CC(c1ccc(O)cc1)O2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 1.00
AKR1B10 O60218 2/20 1.00
AKR1B1 P15121 2/20 1.00
PDPK1 O15530 1/20 1.00
PRKCA P17252 1/20 1.00
BACE1 P56817 1/20 1.00
PRKCQ Q04759 1/20 1.00
ABCG2 Q9UNQ0 4/20 0.81
ESR2 Q92731 2/20 0.81
CACNA1G O43497 2/20 0.81
CACNA1H O95180 2/20 0.81
MAOA P21397 1/20 0.81
PDE5A O76074 1/20 0.81
CYP19A1 P11511 2/20 0.75
PDCD1 Q15116 1/20 0.69
CD274 Q9NZQ7 1/20 0.69
KMT2A Q03164 3/20 0.68
MAPT P10636 2/20 0.68
MEN1 O00255 2/20 0.68
POLB P06746 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isoxanthohumol SCHEMBL30033683 1.00 ESR1 (1.00) ESR1AKR1B10AKR1B1PDPK1PRKCA
Isoxanthohumol SCHEMBL30034254 1.00 ESR1 (1.00) ESR1AKR1B10AKR1B1PDPK1PRKCA
Isoxanthohumol SCHEMBL14092988 1.00 ESR1 (1.00) ESR1AKR1B10AKR1B1PDPK1PRKCA
Isoxanthohumol SCHEMBL904557 1.00 ESR1 (1.00) ESR1AKR1B10AKR1B1PDPK1PRKCA
Munduleaflavanone B SCHEMBL14049994 0.93 ESR1 (0.87) ESR1AKR1B10AKR1B1PDPK1PRKCA
7-O-Methylisoxanthohumol SCHEMBL29929829 0.93 ESR1 (0.87) ESR1AKR1B10AKR1B1PDPK1PRKCA
SCHEMBL30630212 0.92 ESR1 (0.85) ESR1AKR1B10AKR1B1PDPK1PRKCA
SCHEMBL14982147 0.91 ESR1 (0.84) ESR1AKR1B10AKR1B1PDPK1PRKCA
SCHEMBL26113090 0.91 ESR1 (0.82) ESR1AKR1B10AKR1B1PDPK1PRKCA
Sophoraflavanone B SCHEMBL1171435 0.90 ESR1 (1.00) ESR1AKR1B10AKR1B1PDPK1PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112641947-B Screening target spot, application and screening method of anti-tumor drug 沈阳福洋医药科技有限公司 2023-02-03 CN claimed
CN-117551068-B Isofluoside alcohol amine copolymer, preparation method and antibacterial application thereof University of South China (CN) 2026-05-26 CN disclosed
US-20250009620-A1 Oral Care Compositions Comprising Hops Beta Acids THE PROCTER & GAMBLE COMPANY 2025-01-09 US disclosed
WO-2024163921-A2 METHODS AND COMPOSITIONS FOR ALTERING METABOLITES IN HOP PLANTS IMPELLO BIOSCIENCES, INC. (US) 2024-08-08 WO disclosed
US-12042523-B2 Compositions and methods for managing or improving bone disorders, joint disorders, cartilage disorders, or a combination thereof UNIGEN, INC. (US) 2024-07-23 US disclosed
US-20240239732-A1 A METHOD FOR SYNTHESIZING XANTHOHUMOL Proxn Sp. Z o.o. (PL) 2024-07-18 US disclosed
EP-2984072-B1 SYNTHETIC ANALOGUES OF XANTHOHUMOL UNIV PISA (IT) 2024-05-29 EP disclosed
US-20240118263-A1 TARGET FOR SCREENING ANTI-TUMOR DRUG, USE THEREOF AND SCREENING METHOD THEREFOR SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2024-04-11 US disclosed
CN-117551068-A Isofluoside alcohol amine copolymer, preparation method and antibacterial application thereof 南华大学 2024-02-13 CN disclosed
CN-117321028-A Method for synthesizing xanthohumol 普罗克森有限责任公司 2023-12-29 CN disclosed
EP-4153558-B1 A METHOD FOR SYNTHESIZING XANTHOHUMOL PROXN SP Z O O (PL) 2023-08-02 EP disclosed
US-20230201295-A1 Compositions and Methods for Managing or Improving Bone Disorders, Joint Disorders, Cartilage Disorders, or a Combination Thereof UNIGEN, INC. (US) 2023-06-29 US disclosed
EP-3991572-A4 ISOXANTHOHUMOL-CONTAINING COMPOSITION, XANTHOHUMOL-CONTAINING COMPOSITION, METHODS FOR PRODUCING SAME, AND METHODS FOR REDUCING BITTERNESS THEREOF Suntory Holdings Limited (JP) 2023-06-28 EP disclosed
US-20230190852-A1 COMPOSITIONS AND METHODS FOR JOINT HEALTH UNIGEN, INC. (US) 2023-06-22 US disclosed
EP-4153558-A1 A METHOD FOR SYNTHESIZING XANTHOHUMOL Proxn Sp. Z o.o. (PL) 2023-03-29 EP disclosed
US-11554153-B2 Compositions and methods for managing or improving bone disorders, joint disorders, cartilage disorders, or a combination thereof UNIGEN, INC. (US) 2023-01-17 US disclosed
WO-2022233428-A1 A METHOD FOR SYNTHESIZING XANTHOHUMOL DERMOTECH BEAUTY SP. Z O.O. (PL) 2022-11-10 WO disclosed
CN-115068574-A Compositions and methods for joint health 尤妮金公司 2022-09-20 CN disclosed
EP-3991572-A1 ISOXANTHOHUMOL-CONTAINING COMPOSITION, XANTHOHUMOL-CONTAINING COMPOSITION, METHODS FOR PRODUCING SAME, AND METHODS FOR REDUCING BITTERNESS THEREOF Suntory Holdings Limited (JP) 2022-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240118263-A1 TARGET FOR SCREENING ANTI-TUMOR DRUG, USE THEREOF AND SCREENING METHOD THEREFOR SELENOI, GSTK1, GSTP1 ESR1 2690/4885AKR1B10 2130/4885AKR1B1 1722/4885
US-12042523-B2 Compositions and methods for managing or improving bone disorders, joint disorders, cartilage disorders, or a combination thereof MATR3, ACACA, COL2A1 ESR1 4659/4885AKR1B10 1225/4885AKR1B1 1234/4885
US-11554153-B2 Compositions and methods for managing or improving bone disorders, joint disorders, cartilage disorders, or a combination thereof MATR3, ACACA, COL2A1 ESR1 4659/4885AKR1B10 1225/4885AKR1B1 1234/4885
US-20240239732-A1 A METHOD FOR SYNTHESIZING XANTHOHUMOL CYP46A1, CYP51A1, SQLE ESR1 2025/4885AKR1B10 979/4885AKR1B1 1066/4885
US-20250009620-A1 Oral Care Compositions Comprising Hops Beta Acids AP3S1, AP2S1, PROC ESR1 4335/4885AKR1B10 3202/4885AKR1B1 3088/4885
US-20230201295-A1 Compositions and Methods for Managing or Improving Bone Disorders, Joint Disorders, Cartilage Disorders, or a Combination Thereof MATR3, ACACA, COL2A1 ESR1 4659/4885AKR1B10 1225/4885AKR1B1 1234/4885
US-20230190852-A1 COMPOSITIONS AND METHODS FOR JOINT HEALTH PTGES, PTGES3, PTGES2 ESR1 3736/4885AKR1B10 2429/4885AKR1B1 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.